Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
Phase 3negativelevosimendanNegative
AI Analysis
Summary
Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan failed to meet its primary endpoint for treating pulmonary hypertension due to heart failure with preserved ejection fraction. Orion Corporation, the licensor partner, released this negative trial result as inside information.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 LEVEL trial did not reach primary endpoint
Importance:8/10
Sentiment:
-0.85
Phase 3failurepulmonary hypertensionheart failurelevosimendanLEVEL trialprimary endpoint not met
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 10, 2026 11:05 AM